ENTRY D01441 Drug NAME Imatinib mesylate (USAN); Imatinib mesilate (JAN); Gleevec (TN); Glivec (TN) PRODUCT GLEEVEC (Novartis Pharmaceuticals Corporation) GENERIC IMATINIB (Dr.Reddy's Laboratories) IMATINIB MESYLATE (American Health Packaging) IMATINIB MESYLATE (Amneal Pharmaceuticals LLC) IMATINIB MESYLATE (Apotex Corp) IMATINIB MESYLATE (Archis Pharma LLC) IMATINIB MESYLATE (Areva Pharmaceuticals) IMATINIB MESYLATE (Armas Pharmaceuticals) IMATINIB MESYLATE (Armas Pharmaceuticals) IMATINIB MESYLATE (Ascend Laboratories) IMATINIB MESYLATE (Aurobindo Pharma Limited) IMATINIB MESYLATE (BluePoint Laboratories) IMATINIB MESYLATE (CELLTRION USA) IMATINIB MESYLATE (Chartwell RX) IMATINIB MESYLATE (Golden State Medical Supply) IMATINIB MESYLATE (Major Pharmaceuticals) IMATINIB MESYLATE (Mylan Institutional) IMATINIB MESYLATE (Mylan Pharmaceuticals) IMATINIB MESYLATE (QUALLENT PHARMACEUTICALS HEALTH LLC) IMATINIB MESYLATE (Qilu Pharmaceutical) IMATINIB MESYLATE (Sun Pharmaceutical Industries) IMATINIB MESYLATE (Teva Pharmaceuticals USA) IMATINIB MESYLATE (Zydus Lifesciences Limited) IMATINIB MESYLATE (Zydus Pharmaceuticals USA) FORMULA C29H31N7O. CH4SO3 EXACT_MASS 589.2471 MOL_WEIGHT 589.7084 CLASS Antineoplastic DG01918 Tyrosine kinase inhibitor DG03161 BCR-ABL inhibitor Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate REMARK Therapeutic category: 4291 ATC code: L01EA01 Chemical structure group: DG00710 Product (DG00710): D01441 EFFICACY Antineoplastic, Tyrosine kinase inhibitor DISEASE Chronic myeloid leukemia (Philadelphia chromosome positive) [DS:H00004] Acute lymphoblastic leukemia (Philadelphia chromosome positive) [DS:H00001] Myelodysplastic/myeloproliferative diseases [DS:H02410] Mastocytosis [DS:H01511] Hypereosinophilic syndrome (FIP1L1-PDGFRA positive) [DS:H01599] Chronic eosinophilic leukemia (FIP1L1-PDGFRA positive) [DS:H01590] Gastrointestinal stromal tumors (KIT positive) [DS:H01591] TARGET BCR-ABL [HSA_VAR:25v1] [HSA:25] [KO:K06619] FIP1L1-PDGFRA [HSA:5156] [KO:K04363] KIT (CD117) [HSA:3815] [KO:K05091] PATHWAY hsa04010(3815+5156) MAPK signaling pathway hsa05200(25+3815+5156) Pathways in cancer hsa05220(25) Chronic myeloid leukemia METABOLISM Enzyme: CYP3A4 [HSA:1576] INTERACTION STR_MAP map07045 Antineoplastics - protein kinase inhibitors BRITE Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EA BCR-ABL tyrosine kinase inhibitors L01EA01 Imatinib D01441 Imatinib mesylate (USAN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Imatinib D01441 Imatinib mesylate (USAN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D01441 Imatinib mesylate (USAN); Imatinib mesilate (JAN) Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG03161 BCR-ABL inhibitor DG00710 Imatinib D01441 Imatinib mesylate Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG00710 Imatinib D01441 Imatinib mesylate Drug classes [BR:br08332] Antineoplastic DG03161 BCR-ABL inhibitor D01441 Imatinib mesylate Target-based classification of drugs [BR:br08310] Protein kinases Receptor tyrosine kinases (RTK) PDGFR family FIP1L1-PDGFRA D01441 Imatinib mesylate (USAN) <JP/US> KIT (CD117) D01441 Imatinib mesylate (USAN) <JP/US> Non-receptor tyrosine kinases ABL family BCR-ABL [HSA_VAR:25v1] D01441 Imatinib mesylate (USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D01441 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D01441 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D01441 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D01441 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D01441 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D01441 Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG03161 BCR-ABL inhibitor DG00710 Imatinib Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG00710 Imatinib DBLINKS CAS: 220127-57-1 PubChem: 7848504 ChEBI: 31690 LigandBox: D01441 NIKKAJI: J1.337.144J ATOM 42 1 C8x C 33.4600 -13.6500 2 C8y C 33.4600 -12.2500 3 C8x C 32.2700 -11.5500 4 C8x C 31.0100 -12.2500 5 C8y C 31.0100 -13.6500 6 C8x C 32.2700 -14.3500 7 C5a C 29.8200 -14.3500 8 N1b N 28.6300 -13.6500 9 C8y C 27.4400 -14.3500 10 C8x C 26.1800 -13.6500 11 C8y C 24.9900 -14.3500 12 C8y C 24.9900 -15.7500 13 C8x C 26.1800 -16.4500 14 C8x C 27.4400 -15.7500 15 N1b N 23.8000 -13.7200 16 C8y C 22.5400 -14.4200 17 N5x N 21.3500 -13.7200 18 C8y C 20.1600 -14.4200 19 C8x C 20.1600 -15.8200 20 C8x C 21.3500 -16.5200 21 N5x N 22.5400 -15.8200 22 C8y C 18.9000 -13.7200 23 C8x C 18.9000 -12.3200 24 N5x N 17.7100 -11.6200 25 C8x C 16.5200 -12.3200 26 C8x C 16.5200 -13.7200 27 C8x C 17.7100 -14.4200 28 C1b C 34.6500 -11.5500 29 N1y N 35.9100 -12.2500 30 C1x C 35.9100 -13.6500 31 C1x C 37.1000 -14.3500 32 N1y N 38.2900 -13.6500 33 C1x C 38.2900 -12.2500 34 C1x C 37.1000 -11.5500 35 C1a C 39.5500 -14.3500 36 O5a O 29.8200 -15.7500 37 C1a C 23.8000 -16.4500 38 S4a S 34.9300 -16.5900 39 O1d O 34.9300 -15.1900 40 O1d O 34.9300 -17.9900 41 C1a C 33.5300 -16.5900 42 O1d O 36.3300 -16.5900 BOND 45 1 18 19 2 2 19 20 1 3 20 21 2 4 21 16 1 5 3 4 2 6 18 22 1 7 4 5 1 8 5 6 2 9 6 1 1 10 9 10 2 11 10 11 1 12 22 23 2 13 23 24 1 14 24 25 2 15 25 26 1 16 26 27 2 17 27 22 1 18 11 12 2 19 2 28 1 20 12 13 1 21 28 29 1 22 13 14 2 23 14 9 1 24 11 15 1 25 5 7 1 26 29 30 1 27 30 31 1 28 31 32 1 29 32 33 1 30 33 34 1 31 34 29 1 32 15 16 1 33 32 35 1 34 7 36 2 35 7 8 1 36 12 37 1 37 1 2 2 38 8 9 1 39 2 3 1 40 16 17 2 41 17 18 1 42 38 39 2 43 38 40 2 44 38 41 1 45 38 42 1 ///